Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
- PMID: 37007752
- PMCID: PMC10050986
- DOI: 10.5114/pg.2023.125882
Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology
Erratum in
-
Erratum: Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Erratum.Prz Gastroenterol. 2023;18(2):224. doi: 10.5114/pg.2023.129421. Epub 2023 Jul 27. Prz Gastroenterol. 2023. PMID: 37538279 Free PMC article.
Abstract
This paper is an update of the diagnostic and therapeutic recommendations of the National Consultant for Gastroenterology and the Polish Society of Gastroenterology from 2013. It contains 49 recommendations for the diagnosis and treatment, both pharmacological and surgical, of ulcerative colitis in adults. The guidelines were developed by a group of experts appointed by the Polish Society of Gastroenterology and the National Consultant in the field of Gastroenterology. The methodology related to the GRADE methodology was used to assess the quality of available evidence and the strength of therapeutic recommendations. The degree of expert support for the proposed statements was assessed on a 6-point Likert scale. Voting results, together with comments, are included with each statement.
Keywords: colonoscopy; diagnostics; guidelines; treatment; ulcerative colitis.
Copyright © 2023 Termedia.
Conflict of interest statement
PE: Takeda, Janssen-Cilag, Pfizer, Ferring, Recordati, Bristol Myers Squibb. MŁ: Takeda, Janssen-Cilag, Astellas, Ferring. MGK: Abbvie, Astellas, Celltrion, Celgene, Janssen, Ferring, Pfizer, Pharmacosmos, Recordati, Takeda. MK: Takeda, Bristol Myers Squibb, Janssen-Cilag. JR: Takeda, Janssen-Cilag, Abbvie, Bristol-Myers Squibb. GR: Abbvie, Astellas, Janssen-Cilag, Ferring, Pfizer, Pharmacosmos, Recordati, Takeda, Bristol Myers Squibb. PR: Ferring, Janssen-Cilag, Takeda. TB: Takeda. EZ: Bristol-Myers Squibb, Ferring, Janssen-Cilag, Sandoz, Nestle, Takeda. Other co-authors do not report any conflict of interest.
Figures
References
-
- Ramy metodyczne opracowywania postępowania diagnostyczno-terapeutycznego . Agencja Oceny Technologii Medycznych i Taryfikacji (2017). https://www.aotm.gov.pl/zalecenia-kliniczne/narzedzia/ramy-metodyczne/
-
- Zagórowicz E, Walkiewicz D, Kucha P, et al. Nationwide data on epidemiology of inflammatory bowel disease in Poland between 2009 and 2020. Pol Arch Intern Med 2022; 132: 16194. - PubMed
LinkOut - more resources
Full Text Sources